Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a financially sound company with a strong track record of revenue growth and a solid pipeline for future growth. While competition and risks are present in the market, their innovative product offerings and clinical data make them a top player in the diabetes technology industry. With a strong global presence and expanding into the MDI segment, Minimed Group has the potential to continue their positive growth trajectory and retain their position as a market leader.

Bears say

Minimed Group is facing regulatory risk and pressure to provide economically attractive solutions, causing potential competition and limiting pricing power and compressing margins. The company also has limited ability to target customers, and may face reimbursement limitations in the future. Additionally, the company has dealt with FDA warning letters in the past, causing delays in product approvals and potential operational delays. There is no known cure for diabetes and competition is strong in the market, with many other companies offering similar technologies.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.